about
Trial watch - inhibiting PARP enzymes for anticancer therapyTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyUpdates in Therapy for Advanced MelanomaChloroquine and hydroxychloroquine for cancer therapyNimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivoEstrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical UtilityRestoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of lifeDose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.A peptide & peptide nucleic acid synthesis technology for transporter molecules and theranostics--the SPPS.Systemic chemotherapy in the treatment of malignant melanoma.Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registriesState of the art chemotherapeutic management of pediatric brain tumors.Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.Mechanisms of chemoresistance to alkylating agents in malignant glioma.Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents.Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.Time trends in glioblastoma multiforme survival: the role of temozolomide.Temozolomide for treatment of brain metastases: A review of 21 clinical trials.Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomideThe safety of treatments for prolactinomas.Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide.TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.TMZ-BioShuttle--a reformulated temozolomide.Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
P2860
Q26745673-FA7B1AA9-B665-4865-BEC7-579BA9672B76Q26745686-A6629650-2315-4B8B-84C3-6AD80CE3DEC9Q26771119-814F3E2C-19EB-49F6-A459-67EE431B0FF1Q26827797-9AA5B17F-97FE-45D2-A9F9-3C823E948B27Q27853322-516F9841-3CCE-47E9-A421-C1DF6B650F70Q28078465-769F7CC7-03A5-47A3-9FB6-7F3CAB9A3248Q31118089-F0EA976F-C1C6-4B26-ABCB-9C9BEE9A9DD1Q33270398-EC407D90-CE92-4F33-9678-0F518D851042Q33386298-5E51D8A3-1FDC-4E16-8F7F-D4F033BDB41CQ33396801-7A5642F2-6AB5-43A2-BBAE-CCABD82B649CQ33430404-94B28004-D9C7-4780-82DF-C07190D48B02Q33628437-302D9CE4-A45E-4311-9593-7A9BD6DCD95DQ35593968-9D080064-33F1-4174-A910-4126ED673727Q35605776-27EA1825-AF9F-4AD5-84E9-49A67924A8A7Q36492376-6D9E2A4E-10EA-4722-B41C-F2D5CB1B5573Q36555670-F31BE6DA-B57C-41C6-A85E-DCF307888E7FQ36726010-EC5EA86C-B130-428E-825B-BBA0491C71ADQ37038352-FE193BE0-9992-499E-8912-2168926092BEQ37121130-A52E85FB-AA96-47E9-BA71-80B6B054ABBDQ37312701-BFA84577-062C-4695-B161-F3B5DCD21E36Q37576025-961E6ADD-6202-45F6-A6BD-8C0F6FDB9D53Q37865580-85F4B218-047C-4696-BEFA-9A7F2175DD68Q38036217-AA7E40BA-F264-429D-AE04-DF33CAD95E1FQ38726058-CFF024C5-5C6B-4841-ADBA-D161BC1ECF18Q39308847-CCF79663-7ADF-4C54-A033-E7193762268EQ39590618-7D29BD77-8264-4D99-8B9E-9B88C873D2B1Q39939002-CE1CC387-4C9A-47A0-AA50-86B2C2B50416Q40927284-9CC13394-E462-4529-BF72-A0472AFBA8F5Q44471917-4E9BFEB1-1EBD-4C4B-A708-101DC2ED1A6CQ48567066-C0321F18-9310-4BF4-8A46-F2B36274BF2A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Temozolomide: a novel oral alkylating agent.
@ast
Temozolomide: a novel oral alkylating agent.
@en
Temozolomide: a novel oral alkylating agent.
@nl
type
label
Temozolomide: a novel oral alkylating agent.
@ast
Temozolomide: a novel oral alkylating agent.
@en
Temozolomide: a novel oral alkylating agent.
@nl
prefLabel
Temozolomide: a novel oral alkylating agent.
@ast
Temozolomide: a novel oral alkylating agent.
@en
Temozolomide: a novel oral alkylating agent.
@nl
P2860
P356
P1476
Temozolomide: a novel oral alkylating agent.
@en
P2093
M R Middleton
S J Danson
P2860
P356
10.1586/14737140.1.1.13
P577
2001-06-01T00:00:00Z